A PHASE 1B, FIRST IN HUMAN, DOSE ESCALATION AND EXPANSION, MULTICENTER STUDY OF XMT- 1660 IN PARTICIPANTS WITH SOLID TUMORS Monika Chaudhry | June 4, 2022
A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Pembrolizumab Plus Chemotherapy Versus Placebo Plus Chemotherapy for the Treatment of Chemotherapy-Candidate Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative (HR+/HER2-) Locally Recurrent Inoperable or Metastatic Breast Cancer (KEYNOTE-B49) Monika Chaudhry | June 19, 2021
A Phase I/II Open-Label, Safety And Preliminary Efficacy Study Of MRx0518 In Combination With Pembrolizumab In Patients With Advanced Malignancies Who Have Progressed On PD-1/PD-L1 Inhibitors (NSCLC, RCC, Bladder, Breast triple negative) Monika Chaudhry | June 19, 2021
